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Abstract
Objectives—To quantitate extracellular and intracellular zidovudine (ZDV) and lamivudine (3TC)
concentrations in blood and semen of HIV-1–infected men.
Design—Nonblind, single-center, open-label pharmacokinetic (PK) study in 14 subjects receiving
ZDV plus 3TC.
Methods—Paired blood and semen samples were obtained during 1 intensive visit and 3 single time
point visits over 2 weeks. Extracellular ZDV and 3TC concentrations were measured in blood plasma
(BP) and seminal plasma (SP), and intracellular ZDV and 3TC triphosphate (TP) concentrations were
measured in isolated mononuclear cells using validated methods. HIV-1 RNA was measured in blood
and semen. PK parameters were estimated using non-compartmental analysis.
Results—Median (interquartile range [IQR]) SP/BP area under the time-concentration curve over
the 12-hour dosing interval (AUC0–12h) ratios for ZDV and 3TC were 2.28 (1.48 to 2.97) and 6.67
(4.10 to 9.14), respectively, whereas individual SP/BP concentration ratios ranged from 1.9 to 91.4.
Intracellular median (IQR) SP/BP AUC0–12h ratios for ZDV-TP and 3TC-TP were 0.36 (0.30 to 0.37)
and 1.0 (0.62 to 1.30), respectively, whereas individual SP/BP concentration ratios ranged from 0.11
to 2.9. HIV-1 RNA was undetectable in both compartments.
Conclusions—ZDV and 3TC SP exposures are 2- to 6-fold greater than BP exposures. Seminal
ZDV-TP exposures are ~40% of those found in peripheral blood mononuclear cells (PBMCs),
whereas 3TC-TP exposures are similar to PBMC exposures. PK variability makes individual SP/BP
ratios a suboptimal surrogate for genital tract exposure.
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Unprotected sexual intercourse is the predominant risk factor for acquiring HIV, with most
transmission occur- ring from infected men to male and female partners.1 The efficiency of
HIV transmission depends on a variety of factors, including the type of sex act, the viral burden
of the infected partner, and the susceptibility of the uninfected partner to HIV infection.2–7
Although behavioral interventions, such as condom use, have been successful in reducing
transmission,8–10 approximately 4 million adults and children are infected globally on a yearly
basis.1 New and novel prevention methods are urgently needed to slow the spread of the
epidemic.
One potential mechanism to slow HIV transmission is the use of antiretroviral drugs (ARVs)
to reduce HIV RNA concentrations in infectious secretions. ARV therapy has been shown
reliably to decrease HIV RNA concentrations in the genital tract (GT),11–14 and lower semen
HIV RNA concentrations are expected to decrease the efficiency of sexual transmission.
Chakraborty and colleagues4 predict that a semen HIV RNA concentration of 100,000 copies/
mL would result in transmission in 1 per 100 episodes of heterosexual intercourse, whereas a
seminal viral load of 1000 copies/mL would decrease the probability of transmission to 3 per
10,000 acts. The relation between HIV RNA concentrations in blood plasma (BP) and semen
is imperfect,15–18 and careful examination of viral sequences demonstrates that BP and GT
can be viewed as separate viral compartments.19–21 Persistent GT HIV RNA shedding in
subjects receiving ARVs has been reported,22 and long-lived resistant variants in the GT
represent a particular problem for rebound viremia23 and transmitted resistance.19 It seems
likely that poor penetration or altered metabolism of ARVs in the GT contribute to this problem.
24
Nucleoside reverse transcriptase inhibitors (NRTIs) such as lamivudine (3TC) and zidovudine
(ZDV) form the backbone of a typical ARV regimen, and this combination is currently
recommended as an alternative option for initial treatment of HIV infection by the US
Department of Health and Human Services.25 Random BP and seminal plasma (SP)
concentrations of these drugs have been measured previously,14,26,27 and investigators have
noted ZDV and 3TC concentrations to be 2 to 9 times higher in SP than in BP. As with all
NRTIs, however, the active moiety is the triphosphate (TP) metabolite formed by intracellular
enzymatic processes.28 Higher intracellular 3TC-TP and ZDV-TP concentrations in peripheral
blood mononuclear cells (PBMCs) have been correlated with a faster decline in HIV RNA
concentrations and an increase in CD4 T-cell counts.29 TP concentrations have not been
previously characterized in GT mononuclear cells but are likely critical for NRTI efficacy
locally. Here, we report on a comprehensive evaluation of extracellular and intracellular ZDV
and 3TC concentrations in the male GT over a 12-hour dosing interval under steady-state
conditions.
METHODS
Study Design and Population
HIV-infected adult male subjects receiving ZDV/3TC twice daily as part of their ARV regimen
were enrolled in a nonblind, open-label, descriptive pharmacokinetic (PK) study to assess the
relation between parent drug concentration, intracellular drug metabolite concentrations, and
HIV-1 RNA concentrations in BP and SP from May 2000 to June 2003. Subjects were recruited
from the Infectious Disease Clinic at the University of North Carolina at Chapel Hill. Exclusion
criteria included: age ≤17 years; vasectomy; active bacterial, fungal, or opportunistic GT or
systemic infection at the time of enrollment; unwilling or unable to donate semen; abnormal
blood chemistries or blood cell counts; or unable to receive ZDV/3TC for any reason. This
protocol was approved by the Biomedical Institutional Review Board of the University of North
Carolina at Chapel Hill.
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In addition to 300 mg of ZDV and 150 mg of 3TC dosed twice daily, subjects could receive
protease inhibitors or nonnucleoside reverse transcriptase inhibitors as part of the ARV regimen
prescribed by their clinic provider. Subjects received the study regimen for 4 to 48 months
before protocol enrollment. Before the PK visit, subjects completed a 7-day dosing card to
ensure steady-state conditions; for the visit to continue, subjects must have achieved at least
90% adherence overall and have taken all doses in the preceding 3 days. Subjects were then
admitted to the Verne S. Caviness General Clinical Research Center for an overnight stay for
intense BP sampling and 2 semen samples. Matching blood and semen samples were also
obtained at 3 outpatient visits over 2 weeks to complete the PK sampling from the seminal
compartment and to measure HIV-1 RNA response in BP and SP.
Sample Collection and Processing
At the steady-state PK visit, blood samples were obtained immediately before the next dose
(time = 0), and at 0.5, 1, 2, 4, 6, 8, and l2 hours after an observed dose of ZDV/3TC. Semen
samples were obtained by masturbation immediately before dosing at time = 0, and again 12
hours after dosing. Paired BP and SP samples were obtained at 3 outpatient visits over 2 weeks
at 3, 6, and 9 hours after a dose of ZDV/3TC for extracellular concentrations and intracellular
TP concentrations. The time interval between semen collections was designed to avoid
potential effects of repeated sampling on drug concentrations in this compartment. Subsequent
formal study of the effect of sampling interval of ARV concentrations in semen demonstrates
that short sampling intervals have no significant effects on measured concentrations.30
Whole blood was obtained using ethylenediaminetetraacetic acid (EDTA)–containing
collection tubes (BD Diagnostics, Franklin Lakes, NJ) and was centrifuged at 1400 g (2800
rpm) for 15 minutes at 4°C. The resultant BP was aliquoted into labeled cryovials and stored
at −80°C until analysis of extracellular ZDV/3TC concentrations and HIV-1 RNA
concentrations. PBMCs were obtained using 10-mL cell preparation tube (CPT) tubes with
sodium citrate (BD Diagnostics) for intracellular ZDV/3TC concentration analyses. After
collection and centrifugation at 300 g (1300 rpm) for 30 minutes, the resultant plasma and
buffy coat were transferred to a 15-mL Falcon tube and washed with phosphate-buffered saline
(PBS). After an additional centrifugation step, the cell pellet was resuspended and viable
PBMCs were counted with a hemocytometer using the trypan blue exclusion method. After
the cells were repelleted and lysed with methanol, the cellular debris was removed in a final
centrifugation step and the methanolic supernatant containing the TP was transferred to a
labeled cryovial and stored at −80°C until analyses.
Semen samples were collected into a standard specimen collection cup. After collection,
samples were left at room temperature to liquefy for 45 minutes and then centrifuged at 1400
g (2800 rpm) for 15 minutes at room temperature to separate SP from the cellular fraction. SP
aliquots were transferred to labeled cryovials and stored at −80°C until analysis of extracellular
ZDV/3TC concentrations and HIV-1 RNA concentrations. To isolate seminal mononuclear
cells, the cell pellet was resuspended and layered on a Percoll gradient before centrifugation
at 1400 g (2800 rpm) for 20 minutes. The cells were removed from the interface, washed with
PBS, and resuspended. Cells were then counted and processed for storage using the same
method as described previously for PBMCs.
Analytic Methods
Extracellular and intracellular concentrations in blood and semen were measured using
validated and previously published liquid chromatography tandem mass spectrometry (LC/
MS/MS) methods.31,32 The dynamic range for extracellular concentrations of ZDV and 3TC
was 5 to 5000 ng/mL, with a minimum of 90% accuracy, and interday and intraday variability
of 3% to 14% and 1% to 7.6% relative standard deviation (RSD), respectively. The lower limits
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of quantitation (LLQs) for intracellular ZDV-TP and 3TC-TP were 0.10 and 10.5 pmol,
respectively. For concentrations up to 150 pmol, recovery was ≥93%, and the coefficient of
variation (CV) for interday variability ranged from 4.5% to 8.4%. The CV for intraday
variability ranged from 1% to 8%.
HIV-1 RNA concentrations in BP were determined using the Roche Amplicor Monitor kit
(Pleasanton, CA; LLQ = 50 copies/mL) and in SP using the Organon Teknika Nuclisens assay
(Durham, NC; LLQ = 400 copies/mL).
PK parameters, including the area under the time-concentration curve over the 12- hour dosing
interval (AUC0–12h), were estimated for BP and SP using WinNonlin Professional (Version
4.1; Pharsight, Inc., Mountain View, CA). Half-lives were calculated from λz values obtained
from the noncompartmental analysis. For all analyses, concentration measurements lower than
the lower limit of detection were imputed as 0 and those lower than the LLQ were imputed as
½ LLQ. Concentration ratios were calculated to describe differences between drug exposure
in BP and SP for extracellular ZDV and 3TC and intracellular ZDV-TP and 3TC-TP.
RESULTS
Demographic data for the 14 men enrolled in the study are presented in Table 1. These men
ranged in age from 26 to 48 years; 50% were African American and 50% were white. In addition
to ZDV/3TC, most (64%) were also receiving a protease inhibitor or a nonnucleoside reverse
transcriptase inhibitor. At baseline, the median HIV RNA concentration in BP was 2.6 log10
copies/mL and <400 copies/mL in SP; the median CD4 T-cell count was 512 cells/mm3. Men
were followed in this study for 2 to 44 weeks. Over this period, HIV RNA levels declined to
undetectable concentrations in blood and semen in all but 1 participant. This subject had been
receiving a stable regimen of ZDV/3TC for 3.5 years before enrollment and had undetectable
HIV RNA in BP up to 32 weeks after enrollment, with a single detectable HIV RNA
measurement of 880 copies/mL at 2 weeks of enrollment.
Table 2 presents median (interquartile range [IQR]) AUC0–12h in SP and BP for ZDV and 3TC
and their intracellular TP metabolites. Five of 112 total ZDV BP samples were lower than the
LLQ, and imputed values were used for these samples; all other samples were within the
quantitation limits for each assay. For ZDV, the AUC0–12h in SP was 3790 (IQR: 2481 to 4783)
h·ng/mL, whereas the AUC0–12h in BP was 1479 (IQR: 1175 to 1748) h·ng/mL. By dividing
each subject’s SP AUC0–12h by their respective BP AUC0–12h, the SP/BP exposure ratio was
calculated. Using this AUC ratio approach, rather than using the SP/BP ratios of concentrations
obtained at individual time points, provided a robust overall estimate of GT drug penetration.
For ZDV, the median (IQR) SP/BP AUC0–12h ratio was 2.28 (1.48 to 2.97), indicating that
ZDV exposure in SP was twice that of BP. For 3TC, the median (IQR) SP/BP AUC0–12h was
6.67 (4.10 to 9.14), indicating that 3TC exposure in SP was >6 times that of BP.
In Figure 1A, the median (IQR) time-concentration profile for ZDV depicts higher exposures
in SP than in BP over the dosing interval. The maximal concentration (Cmax) observed in each
compartment was similar (median SP Cmax = 561 ng/mL, median BP Cmax = 785 ng/mL).
Using the available data, the median ZDV half-lives in SP and BP were 6.9 hours and 2.7 hours,
respectively.
Figure 1B illustrates 3TC concentrations in SP consistently higher than in BP throughout the
dosing interval. Generally, SP concentrations remained constant across the dosing interval.
The median 3TC half-lives in SP and BP were calculated to be 7.1 hours and 3.8 hours,
respectively.
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Figure 2 depicts the median (IQR) TP PK in blood and semen for ZDV-TP (see Fig. 2A) and
3TC-TP (see Fig. 2B). These concentrations were more consistent across the dosing interval
than extracellular ZDV and 3TC. For ZDV-TP, the PBMC and seminal mononuclear cell
median (IQR) half-lives were 25.0 (5.5 to 28.5) and 14.2 (12.9 to 14.3) hours, respectively.
For 3TC-TP, PBMCs and seminal mononuclear cell median (IQR) half-lives were 10.4 (3.3
to 23.1) and 10.2 (1.2 to 22.2) hours, respectively.
For ZDV-TP, the median (IQR) AUC0–12h in SP was 646 (361 to 1029) h·fmol/106 cells,
whereas the median (IQR) AUC0–12h in BP was 1460 (1241 to 2172) h·fmol/106 cells. The
SP/BP ratio for ZDV-TP was 0.36 (IQR: 0.30 to 0.37). For 3TC-TP, the median (IQR)
AUC0–12h in SP was 82,068 (64,342 to 139,404) h·fmol/106 cells, whereas the AUC0–12h in
BP was 108,600 (IQR: 78,687 to 164,984) h·fmol/106 cells, yielding an SP/BP ratio of 1.0
(IQR: 0.62 to 1.30). Although extracellular GT concentrations were higher than BP, the
intracellular TP concentrations in seminal mononuclear cells were similar to, or lower than,
PBMC concentrations. For ZDV-TP, the SP/BP AUC0–12h of 0.36 indicates that the seminal
cell exposure was approximately 40% that of PBMCs. The SP/BP AUC0–12h ratio of 1.0 for
3TC-TP indicates equivalent exposure, however.
Figure 3 compares SP/BP concentration ratios at each collection point for the 4 analytes. The
concentration ratios for ZDV-TP and 3TC-TP did not differ appreciably over time, whereas
they were highly dependent on the time of sampling for parent ZDV and 3TC. For ZDV and
3TC, individual SP/BP concentration ratios ranged from 1.9 to 91.4 and from 1.9 to 30.5,
respectively, with CVs ranging from 60% to 285%. In comparison, parent drug AUC0–12h ratio
CVs ranged from 48% to 87%. Samples obtained early in the dosing interval gave lower SP/
BP ratios, whereas those obtained later in the dosing interval gave higher ratios. This is
particularly evident for ZDV, which maintains high concentrations in SP over a dosing interval,
whereas BP concentrations decline quickly. For ZDV-TP and 3TC-TP, individual SP/BP
concentration ratios ranged from 0.11 to 2.9 and from 0.14 to 2.5, respectively.
Correlation analysis to investigate potential relations between extracellular parent drug and the
TP metabolite exposures in SP and BP did not provide strong evidence of a direct relation for
ZDV or 3TC (r < 0.6, P > 0.07 for all analyses; data not shown).
DISCUSSION
This is the first study designed to provide full extracellular and intracellular PK profiles in
blood and semen for ZDV and 3TC. Using calculated AUCs in this investigation, ZDV SP
exposure was approximately 2 times greater than BP exposure, and 3TC SP exposure was
approximately 6 times greater than BP exposure. Three previous reports of ZDV and 3TC
concentrations in SP using isolated time points reported ZDV and 3TC SP exposures ranging
from 2.16- to 9.1-fold greater than BP exposures.14,26,27 By obtaining several timed samples
over 2 weeks, this investigation was able to calculate an AUC0–12h in SP, which, when
compared with the AUC0–12h in BP, provides a more accurate estimate of drug penetration
over a dosing interval.
Different ARV exposures in the GT relative to BP have been reported for men and women,
14,24,33–40 and the exact physiochemical properties that govern drug passage into GT
secretions are currently unknown. Differences exist between classes of agents and between
specific agents within each class. This behavior in the male GT is consistent with steady-state
GT behavior in women (3TC 4-fold higher in GT, ZDV 2-fold higher in GT).24
Similar to our previous report for the nonnucleoside agent efavirenz,33 extracellular ZDV and
3TC individual SP/BP concentration ratios change considerably in a single subject over the
dosing interval because of different rates of drug penetration into the GT. Therefore, the use
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of AUC0–12h ratios provided a more robust measure of overall drug exposure in SP relative to
BP. This can be seen by the lower CVs for AUC0–12h ratios (range: 48% to 87%) compared
with individual concentration ratios (range: 60% to 285%). Given the logistics of seminal
sample collection for constructing an AUC0–12h, however, there is some increased variability
around the estimates of individual PK parameters (particularly Cmax).
Unexpectedly, this investigation found that elevated extracellular ZDV and 3TC exposures in
semen did not result in elevated intracellular TP exposures. Although 3TC exposure was
approximately 6-fold higher in semen than in blood, 3TC-TP exposure in seminal mononuclear
cells was similar to that in PBMCs. Despite 2-fold higher ZDVexposure in SP compared with
BP, ZDV-TP exposure in seminal mononuclear cells was only approximately 40% of that
measured in PBMCs.
Our subjects were patients on therapy for HIV infection, and as such, sampling was limited to
within a dosing interval. Although this approach can underestimate half-life, the long
intracellular half-life estimates of ZDV-TP and 3TC-TP reported here (median values of 10.2
to 25.0 hours) are similar to those reported elsewhere in PBMCs.32,41,42 The more stable TP
concentrations observed over the dosing interval suggest that a single SP/BP concentration
ratio may serve as a reasonable proxy for overall intracellular drug exposure in the male GT.
Because collection, processing, and analysis of PBMCs and seminal mononuclear cells are
complex procedures, using single time points rather than multiple sampling strategies could
facilitate research in this area.
The differential TP exposures between PBMCs and seminal mononuclear cells observed here
may be attributable to differential cellular activation or different cell populations between the
2 compartments. 3TC (a cytidine analogue) and ZDV (a thymidine analogue) have different
intracellular metabolic pathways for activation.28 The enzymes involved in these pathways can
be affected by cellular factors, such as growth phase and activity.28 ZDV is preferentially
phosphorylated in activated cells,43,44 whereas 3TC is preferentially phosphorylated in
quiescent cells.45 These subjects had been on stable therapy for at least 6 months and had been
screened for sexually transmitted diseases (STDs) before participating in this study. Therefore,
fewer activated mononuclear cells in the male GT could account for the low SP/BP ratio of
ZDV-TP. There are currently no data on intracellular drug concentrations in the GT of men
with ongoing HIV replication or an active STD, however.
Differential phosphorylation between SP and BP may also be explained by diverse cell
populations in the 2 compartments. The distribution of mononuclear cell subsets in semen is
unknown. It has recently been observed in PBMCs that different cell types may phosphorylate
nucleosides to varying extents, however.46
At the end of the 2-week treatment period, all subjects had undetectable HIV RNA
concentrations in BP and all but 1 subject had undetectable HIV RNA in SP. It is notable that
this subject had the lowest intracellular seminal exposure for ZDV-TP and 3TC-TP.
Unfortunately, viral sequencing could not be performed on his samples.
The small number of men in this cohort precluded meaningful statistical evaluations of drug
concentrations with HIV RNA and/or CD4 T-cell response. Other researchers have reported
correlations between TP concentrations in PBMCs and drug efficacy,29 with higher TP
concentrations leading to faster declines in HIV-1 RNA and quicker improvements in CD4
cell counts. Future PK-pharmacodynamic modeling with these data to explore the highly
complex intracellular-extracellular drug concentration relation in BP and SP is planned but is
outside the scope of this article.
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The GT pharmacology data presented here are important for the health of the HIV-infected
individual and to gain insight into the development of drug resistance in the GT. Understanding
the pharmacology of nucleoside analogue reverse transcriptase inhibitors, the backbone of
ARV therapy, is critical for choosing agents that minimize the development of resistance in
the GT. Lower active ZDV concentrations in seminal cells may provide a pharmacologic basis
for the male GT as a sanctuary site for HIV replication. Sexual transmission of resistant HIV
is becoming increasingly common as ARV treatment becomes more widely available,19,47–
53 and the choice of drug regimen clearly drives HIV resistance patterns in the male and female
GT compartments.54–56 In addition to these seminal TP data for 3TC and ZDV, tenofovir
diphosphate concentrations in seminal mononuclear cells have recently been reported to be 5
times higher than in PBMCs at steady state.34 The ability of tenofovir diphosphate to be equally
phosphorylated in activated and quiescent cells may partially explain the high intracellular
concentrations,44 although other factors currently under investigation may contribute to these
differences.
For prevention of HIV transmission, these data are most critical for elucidating the influence
of local drug concentrations on HIV shedding and the development of drug resistance. To
assess the ability of drugs to act locally and protect HIV-negative individuals from infection,
tissue concentrations of ARVs in the rectum, penile foreskin, and vaginal/cervical mucosa
would be the most relevant to evaluate.
HIV is found in all male GT compartments, including organs that contribute to the generation
of semen (ie, prostate, seminal vesicles, testicles). Some differences may be observed in the
penetration of ARVs into each of these compartments, but they are unlikely to be clinically
relevant.57 Recent developments in techniques to measure the fraction of the total drug
concentration contributed by seminal vesicle–derived fluid and prostatic fluid should continue
to advance the understanding of GT pharmacology and implications for local drug resistance.
58
In conclusion, this is the first study to report ZDV, ZDV-TP, 3TC, and 3TC-TP exposures over
a dosing interval in SP and seminal mononuclear cells in comparison to BP and PBMCs. These
data have implications for development of compartmental resistance and further assist us in
understanding ARV activity in the male GT.
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A, Median (IQR) extracellular ZDV parent concentrations in BP and SP over the 12-hour
dosing interval. Semen collection occurred longitudinally at steady state to construct a
composite concentration-time profile. B, Median/IQR extracellular 3TC parent concentrations
in BP and SP over the 12-hour dosing interval. Semen collection occurred longitudinally at
steady state to construct a composite concentration-time profile.
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A, Median (IQR) ZDV-TP concentration-time profile in blood (◆) and semen (○) over the
12-hour dosing interval. Subjects received 300 mg of ZDV twice daily. Semen collection
occurred longitudinally at steady state to construct a composite concentration-time profile. B,
Median/IQR 3TC-TP concentration-time profile in blood (◆) and semen (○) over the 12-hour
dosing interval. Subjects received 150 mg of 3TC twice daily. Semen collection occurred
longitudinally at steady state to construct a composite concentration-time profile.
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Median (IQR) SP/BP concentration ratios at each collection point for ZDV, 3TC, ZDV-TP,
and 3TC-TP. Ratios were obtained by dividing the SP concentration at each time point by the
corresponding BP concentration.
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TABLE 1
Demographic and Drug Regimen Information for Study Subjects
Parameter
 Age (y) 36 (34 to 40)
 Blood HIV RNA (log10 copies/mL) 2.6 (1.87 to 2.67)
 CD4 T-cell count (cells/μL) 512 (388 to 773)
 Length of follow up (wk) 4 (2 to 33)
 Race
  African American 7 (50%)
  White 7 (50%)
Drug regimen (n = 14)
 ZDV/3TC 5 (36%)
 ZDV/3TC + NNRTI* 4 (28%)
 ZDV/3TC + PI† 5 (36%)
Data are presented as median (IQR) or number (percent).
*
Three men received efavirenz; 1 man received nevirapine.
†
Three men received nelfinavir; 2 men received indinavir.
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TABLE 2
Median (IQR) AUC0–12h Values for ZDV and 3TC in BP and SP and ZDV-TP and 3TC-TP
ZDV (h·ng/mL) ZDV-TP (h·fmol/106 cells) 3TC (h·ng/mL) 3TC-TP (h·fmol/106 cells)
AUC0–12h BP 1479 (1175 to 1748) 1460 (1241 to 2172) 4924 (4373 to 6237) 108,600 (78,687 to 164,984)
AUC0–12h SP 3790 (2481 to 4783) 646 (361 to 1029) 31,084 (28,071 to 44,184) 82,068 (64,342 to 139,404)
SP/BP ratio 2.28 (1.48 to 2.97) 0.36 (0.30 to 0.37) 6.67 (4.10 to 9.14) 1.0 (0.62 to 1.30)
Median (IQR) of the SP/BP ratios of each provides an estimate of SP exposure relative to BP.
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